logo-loader
viewOxidien Pharmaceuticals

Oxidien Pharmaceuticals addressing an unmet need in kidney disease

Oxidien Pharmaceuticals CEO Helena Cowley spoke with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Florida-based clinical stage biopharmaceutical company is focused on addressing kidney disease. It recently received encouraging responses from the FDA regarding their its proposed Phase 1/2 trial in secondary hyperoxaluria patients.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fax Capital CEO talks investment and aligning with the right...

Fax Capital (TSE: FXC-) CEO Blair Driscoll joined Steve Darling from Proactive Vancouver to discuss the investment holding company that intends to invest in approximately 10 to 15 high-quality small-cap public and private businesses located primarily in Canada. Driscoll tells Proactive why...

10 hours, 51 minutes ago

2 min read